Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Access to treatment for opioid dependence in rural America: challenges and future directions.

Sigmon SC.

JAMA Psychiatry. 2014 Apr;71(4):359-60. doi: 10.1001/jamapsychiatry.2013.4450. No abstract available.

PMID:
24500040
2.

Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, Patkar A, Chavoustie S, Blasey C, Sigmon S, Beebe KL.

Addiction. 2013 Dec;108(12):2141-9. doi: 10.1111/add.12315. Epub 2013 Sep 18.

PMID:
23919595
3.

Buprenorphine implants and opioid dependence.

Rastegar DA.

JAMA. 2011 Jan 19;305(3):253; author reply 254-5. doi: 10.1001/jama.2010.1988. No abstract available.

PMID:
21245178
4.

Buprenorphine implants and opioid dependence.

Basu D, Kumar V.

JAMA. 2011 Jan 19;305(3):253-4; author reply 254. doi: 10.1001/jama.2010.1989. No abstract available.

PMID:
21245177
5.

Advances in the treatment of opioid dependence: continued progress and ongoing challenges.

O'Connor PG.

JAMA. 2010 Oct 13;304(14):1612-4. doi: 10.1001/jama.2010.1496. No abstract available.

PMID:
20940391
6.

Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.

Ling W, Casadonte P, Bigelow G, Kampman KM, Patkar A, Bailey GL, Rosenthal RN, Beebe KL.

JAMA. 2010 Oct 13;304(14):1576-83. doi: 10.1001/jama.2010.1427.

PMID:
20940383
7.

Favorable mortality profile of naltrexone implants for opiate addiction.

Reece AS.

J Addict Dis. 2010 Jan;29(1):30-50. doi: 10.1080/10550880903435988.

PMID:
20390697
8.

Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.

White J, Bell J, Saunders JB, Williamson P, Makowska M, Farquharson A, Beebe KL.

Drug Alcohol Depend. 2009 Jul 1;103(1-2):37-43. doi: 10.1016/j.drugalcdep.2009.03.008. Epub 2009 Apr 28.

PMID:
19403243
9.

Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.

Reece AS.

J Subst Abuse Treat. 2009 Oct;37(3):256-65. doi: 10.1016/j.jsat.2009.03.008. Epub 2009 Apr 25.

PMID:
19394789
10.

Novel depots of buprenorphine have a long-acting effect for the management of physical dependence to morphine.

Liu KS, Kao CH, Liu SY, Sung KC, Kuei CH, Wang JJ.

J Pharm Pharmacol. 2006 Mar;58(3):337-44.

PMID:
16536900
11.

In-vitro and in-vivo characterization of a buprenorphine delivery system.

Kleppner SR, Patel R, McDonough J, Costantini LC.

J Pharm Pharmacol. 2006 Mar;58(3):295-302.

PMID:
16536895
12.

Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.

Stinus L, Cador M, Zorrilla EP, Koob GF.

Neuropsychopharmacology. 2005 Jan;30(1):90-8.

13.

Development of biodegradable drug delivery system to treat addiction.

Mandal TK.

Drug Dev Ind Pharm. 1999 Jun;25(6):773-9.

PMID:
10349563
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk